Allergan plc (AGN)

NYSE - NYSE Real Time Price. Currency in USD
225.29-0.64 (-0.28%)
At close: 4:02 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close225.93
Bid218.00 x 100
Ask230.00 x 100
Day's Range224.87 - 226.66
52wk Range195.50 - 322.68
1y Target EstN/A
Market Cap89.2B
P/E Ratio (ttm)21.45
Avg Vol (3m)3,299,435
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Hedge Funds Are Cashing Out Of These Stocks As Investors Yank Capital
    Insider Monkey19 hours ago

    Hedge Funds Are Cashing Out Of These Stocks As Investors Yank Capital

    It has been a disastrous stretch for hedge funds in terms of investor retention. According to a report from Hedge Fund Research, investors pulled $28 billion from hedge funds during the last three months, the biggest quarterly money withdrawal since 2009. Total outflows for the year stood at $55.9 billion as of the end of […]

  • PR Newswire20 hours ago

    KYBELLA® (deoxycholic acid) injection 10 mg/mL Puts "Profiles in Focus" With Expert Panel And New Direct-To-Consumer Campaign

    DUBLIN, Oct. 25, 2016 /PRNewswire/ -- Studies show that more than two-thirds of aesthetically-oriented consumers are bothered by submental fullness, or "double chin."1 And with social media profile images becoming more important than ever, there is interest in looking one's best.

  • PR Newswire21 hours ago

    Allergan Successfully Completes Vitae Tender Offer

    DUBLIN, Oct. 25, 2016 /PRNewswire/ -- Allergan plc (AGN), a leading global pharmaceutical company, today announced the successful completion of Allergan's tender offer to purchase all outstanding shares of Vitae Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on innovative development programs for dermatologic conditions.  As previously announced, Allergan offered to purchase all outstanding shares of Vitae for $21.00 per share, in cash, for a total transaction value of approximately $639 million. The acquisition strengthens Allergan's dermatology product pipeline, with the addition of VTP-43742, a Phase 2 first-in-class, orally active RORγt (retinoic acid receptor-related orphan receptor gamma) inhibitor for the potential treatment of psoriasis and other autoimmune disorders.